title: Circulating miR-195 as a Therapeutic Biomarker in Turkish Breast Cancer Patients.
abstract: BACKGROUND
  Dysregulation of miRNA expression may be used as a biomarker for specific tumours because it may contribute to development of cancer. Circulating miRNA profiles have been highlighted for their potential as predictive markers in heterogeneous diseases such as breast cancer. In the literature, there is evidence that miR-195 levels are differentially expressed pre- and post-operative periods in breast cancer patients. At the same time, miRNA expression levels may vary because of ethnic origins. This study aimed to determine expression levels and potential roles of miR-195 in Turkish breast cancer patients.
  
  
  METHODS
  The expression patterns of miR-195 were initially examined in breast cancer tissues (luminal A and B type) (n=96). Subsequently, blood samples were prospectively collected from preoperative and postoperative Turkish breast cancer patients and disease free controls. Total RNA was isolated, and the expression level of miR-195 was quantified by real-time PCR.
  
  
  RESULTS
  We found that miR-195 level was altered in Turkish breast cancer patients, with down-regulation evident in breast cancer tissues compared to normal adjacent specimens. Furthermore, circulating levels of miR- 195 was significantly decreased in post-operative blood samples compared with pre-operative levels (p=0.01 and <0.05). However, miR-195 was significantly increased in pre-operative blood samples of the luminal B type (p= 0.04 and <0.05).
  
  
  CONCLUSIONS
  This study represents the first report of a miR-195 expression profile in Turkish breast cancer patients. Our data suggests that miR-195 levels might be a clinically useful biomarker in the earliest stage of Turkish breast cancer patients.
authors: Department of Medical Biology, Medical Faculty, Uludag University, Turkey E-mail : gcecener@uludag.edu.tr.
authors: Gulsah
authors: G
authors: Cecene
authors: Secil
authors: S
authors: Ak
authors: Gamze Guney
authors: GG
authors: Eskiler
authors: Elif
authors: E
authors: Demirdogen
authors: Elif
authors: E
authors: Erturk
authors: Sehsuvar
authors: S
authors: Gokgoz
authors: Volkan
authors: V
authors: Polatkan
authors: Unal
authors: U
authors: Egeli
authors: Berrin
authors: B
authors: Tunca
authors: Gulcin
authors: G
authors: Tezcan
authors: Ugur
authors: U
authors: Topal
authors: Sahsine
authors: S
authors: Tolunay
authors: Ismet
authors: I
authors: Tasdelen
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D001943:Breast Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000097:blood* / Q000556:secondary / Q000601:surgery; D018275:Carcinoma, Lobular / Q000097:blood* / Q000556:secondary / Q000601:surgery; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D060888:Real-Time Polymerase Chain Reaction; D014421:Turkey; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; C552722:MIRN195 microRNA, human; D035683:MicroRNAs